News of Note—Curevo, Merck, Inovio and more

In this week's news of note, Merck's experimental Ebola vaccine has been deployed in Congo. (Pixabay)

In conjunction with the Infectious Disease Research Institute and Mogam Institute for Biomedical Research, South Korea's GC Pharma formed a new company in Seattle dubbed Curevo to conduct vaccine R&D. Release

A new study from the American Society for Microbiology and Research America found that the U.S. public's confidence in vaccines has slipped from 2008. U.S. News & World Report story

Inovio Pharmaceuticals started a phase 2 study of its cancer vaccine VGX-3100 in patients with HPV-related anal dysplasia. Release

Merck's experimental Ebola vaccine has been deployed against an outbreak in the Democratic Republic of Congo. Reuters story

FluGen kicked off a study testing its universal flu vaccine candidate's ability to protect against a flu strain mismatched by 6 years. Release

In an interim analysis of a phase 2 trial, MimiVax said its SurVaxM provided a significant survival benefit in newly diagnosed glioblastoma patients over historical standard of care. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.